Author/Authors :
Kuranishi, Fumito Department of Surgery - Innoshima-Ishikai Hospital - Innoshima - Onomichi - Hiroshima 722-2211, Japan , Imaoka, Yuki Department of Surgery - Innoshima-Ishikai Hospital - Innoshima - Onomichi - Hiroshima 722-2211, Japan , Sumi, Yuusuke Department of Surgery - Innoshima-Ishikai Hospital - Innoshima - Onomichi - Hiroshima 722-2211, Japan , Uemae, Yoji Cell-Medicine - Inc., 2-1-6 Sengen - Tsukuba - Ibaraki 305-0074, Japan , Yasuda Kurihara, Hiroko Cell-Medicine - Inc., 2-1-6 Sengen - Tsukuba - Ibaraki 305-0074, Japan , Ishihara, Takeshi Cell-Medicine - Inc., 2-1-6 Sengen - Tsukuba - Ibaraki 305-0074, Japan , Miyazaki, Tsubasa Cell-Medicine - Inc., 2-1-6 Sengen - Tsukuba - Ibaraki 305-0074, Japan , Ohno, Tadao Cell-Medicine - Inc., 2-1-6 Sengen - Tsukuba - Ibaraki 305-0074, Japan
Abstract :
Introduction. No efective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete
response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively
including autologous formalin-fxed tumor vaccine (AFTV). Patients and Methods. AFTV was prepared individually for each
patient from their own formalin-fxed and parafn-embedded breast cancer tissues. Results. Tree patients maintained cCR status
of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) afer comprehensive
treatments including AFTV. Te median overall survival time (60.0 months) and the 3- to 8-year survival rates afer diagnosis of
bone metastasis were greater than those of historical control cohorts in Japan (1988–2002) and in the nationwide population-based
cohort study of Denmark (1999–2007). Conclusion. Bone-metastatic breast cancer may be curable afer comprehensive treatments
including AFTV, although larger scale clinical trial is required.
Keywords :
Clinical Complete Response , Rate , Bone-Metastatic , Breast Cancer , Comprehensive Treatments , Autologous Formalin-Fixed Tumor Vaccine